Nvidia Advances AI Drug Discovery, Quantum Models; JPMorgan Sets $265 Target
NVDA•Nvidia unveiled an AI-powered drug discovery platform and quantum-AI models while rolling out its Blackwell and Vera Rubin full-stack systems to boost monetization per deployment. Shares trade at about 24x forward P/E and 13x forward P/S on projected 72% FY2027 revenue growth, with JPMorgan setting a $265 target as the valuation gap with Alphabet falls below $200 billion.
1. AI-Driven Drug Discovery and Quantum Models
Nvidia introduced its AI-powered drug discovery platform alongside new quantum-AI models, marking a push into computational biotechnology and next-generation artificial intelligence.
2. Full-Stack AI Systems Enhance Monetization
The rollout of Blackwell and Vera Rubin architectures shifts the company from chip supplier to end-to-end AI factory provider, increasing revenue per deployment through integrated hardware and software stacks.
3. Valuation Metrics Reflect Rapid Growth
Shares trade at approximately 24x forward P/E and 13x forward P/S despite projected 72% revenue growth in FY2027, indicating significant multiple compression amid robust expansion.
4. $265 Price Target and Market Position
JPMorgan raised its price target to $265 on Nvidia as the valuation gap with Alphabet narrows to below $200 billion, underscoring its leadership in AI and data center systems.
